Age-related macular degeneration market players and analysis by type, by state, by age group, by treatment, by route of administration, by region- forecast till 2030. The treatments for age-related macular degeneration market is expected to reach USD 14.9 billion by 2030, growing at a 8.10% CAGR, states the latest Market Research Future (MRFR) report. The retina has a problem called age-related macular degeneration, or AMD. When the macula, a portion of the retina, is injured, this occurs. People who suffer from age-related macular degeneration experience central visual loss. They cannot see minute details, whether they are close or far. The condition of a person’s macula influences their ability to read, recognise faces, use a phone or computer, watch television, drive, and conduct other visual tasks that need them to see fine detail. Some of the causes of AMD include pale eye colour, a poor diet, genetic predispositions, high blood pressure, UV radiation, high cholesterol, smoking, and obesity.
Various factors are propelling the age-related macular degeneration market growth. Such factors, according to the latest Market Research Future report, include rising government spending on healthcare to cut down healthcare burden on patients, increasing incidence of chronic diseases, increasing pipeline of age-related macular degeneration therapeutics, surging geriatric population, and various medications going off-patent.
On the other hand, the expansion of the age-related macular degeneration market during the projected period may be constrained by strict FDA restrictions, high costs, and the growing use of off-label medications to treat the condition.
Age-related macular degeneration market players
- Bausch & Lomb Incorporate
- Santen Pharmaceuticals Co.
- Alimera Sciences Inc.
- Rxi Pharmaceuticals Inc.
- Regeneron Pharmaceutical Inc.
- Bayer AG
- GlaxoSmithKline PLC
- Ophthotech Corporation
- Acucela Inc.
- F. Hoffmann-La Roche AG
- Novartis AG, Pfizer Inc.
The Market Research Future report offers a complete segmental analysis of the age-related macular degeneration market based on end user, route of administration, treatment, age group, stages, and type.
By type, the age-related macular degeneration market is segmented into dry age-related macular degeneration (dry AMD) and wet age-related macular degeneration (wet AMD). Of these, the wet age-related macular degeneration (wet AMD) segment will lead the market during the forecast period.
By stages, the age-related macular degeneration market is segmented into late-stage age-related macular degeneration, early-stage age-related macular degeneration, and intermediate-stage age-related macular degeneration. Of these, the intermediate-stage age-related macular degeneration segment will dominate the market during the forecast period.
By age group, the age-related macular degeneration market is segmented into 40 years, above 60 years, and above 75 years. Of these, the above 75 years segment will have the maximum share in the market during the forecast period.
By treatment, the age-related macular degeneration market is segmented into diagnosis and treatment. Of these, the treatment segment will dominate the market during the forecast period.
By route of administration, the age-related macular degeneration market is segmented into the intravenous route of administration and intravitreal route of administration. Of these, the intravitreal route of administration will have the largest share in the market during the forecast period.
By end user, the age-related macular degeneration market is segmented into academic research institutes, diagnostic centers, and hospitals & clinics. Among these, hospitals and clinics will lead the market during the forecast period.
By region, the age-related macular degeneration market report covers the latest trends and growth opportunities across the Americas, the Asia Pacific, the Middle East and Africa, and Europe. Of these, the Americas will outweigh the other regions in the market during the forecast period for increasing aging population coupled with rising ophthalmological disorders.
During the projection period, Europe’s market for age-related macular degeneration will hold the second-largest market share. The market for treatments for age-related macular degeneration in the area is expanding as a result of numerous causes, including rising patient demand, expanding healthcare infrastructure, bettering governmental initiatives, rising patient population, and rising elderly population.
The age-related macular degeneration market in the APAC region will grow at the fastest pace during the forecast period. Various factors are propelling the growth of the age-related macular degeneration market in the region, such as the emergence of several players, multinational companies shifting towards developing nations as well as setting operational set-ups, increasing healthcare spending, and increasing incidence of eye disorders. Japan is a major contributor in this region.
The age-related macular degeneration market in the MEA will have restricted growth during the forecast period for limited access and limited healthcare affordability. The market growth in the Middle East is due to increasing healthcare expenditure and increasing healthcare infrastructure.
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5Th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)